WWL70

• Description :

  WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.

• UNSPSC :

  12352005

• Target :

  MAGL

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/WWL70.html

• Purity :

  99.95

• Solubility :

  DMSO : 17.33 mg/mL (ultrasonic)

• Smiles :

  O=C(OC1=CC=C(C2=CC=C(C(N)=O)C=C2)C=C1)N(C)CC3=CC=CC(C4=CC=NC=C4)=C3

• Molecular Formula :

  C27H23N3O3

• Molecular Weight :

  437.49

• References & Citations :

  [1]Li W, et al. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc. 2007 Aug 8;129 (31) :9594-5.|[2]Tanaka M, et al. WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation. 2017 Jan 10;14 (1) :7.|[3]Tchantchou F, et al. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma. 2013 Apr 1;30 (7) :565-79.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [947669-91-2]